Novel CAR T cell therapy developed by UT MD Anderson researchers moves into clinical studies
The novel therapy targets CD94+ relapsed or refractory T/NK cell lymphomas
UT MD Anderson received Investigational New Drug clearance from the Food and Drug Administration to begin Phase 1 clinical trial
The University of Texas MD Anderson Cancer Center and CTMC, a joint venture between UT MD Anderson and Resilience, today announced that the Food and Drug Administration (FDA) has issued a ‘safe to proceed’ for the Investigational...
Novel tool helps identify key targets to strengthen CAR NK cell therapies
Researchers developed the first genome-wide CRISPR screening tool for primary human natural killer (NK) cells
Study revealed critical regulators...
Researchers identify key B-cell lymphoma traits linked with greatest benefit from CD19 CAR T cell therapy
Largest study of its kind provides new insights on lymphoma biology to guide clinical approaches
Researchers identified three subgroups with...
ASCO: New antibody-drug conjugate shows promising safety and response rates for patients with rare blood cancer
Blastic plasmacytoid dendric cell neoplasm (BPDCN) is a rare, aggressive blood cancer that often involves the bone marrow, skin and, sometimes, lymph nodes.
First-in-class antibody-drug conjugate, pivekimab sunirine (PVEK), was safe and effective.
PVEK achieved an overall response rate of 85% and complete response rate of 70% as frontline treatment in newly diagnosed patients with BPDCN.
Findings suggest this treatment should be considered...
NK cells complexed with bispecific antibody yield high response rates in patients with lymphoma
HOUSTON ― A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a CD30/...
ASH: Triplet combination regimens demonstrate high response rates in multiple leukemias
ABSTRACTS: 216, 219, 1011
SAN DIEGO ― Three clinical trials led by researchers from The University of Texas MD Anderson...
ASH: Monoclonal antibody therapy improves survival in cancer-associated hyper-inflammatory disorder
ABSTRACT: 805
SAN DIEGO – Adult patients with newly diagnosed malignancy-associated hemophagocytic lymphohistiocytosis (mHLH) – a rare...
Novel CAR T cell therapy obe-cel demonstrates high response rates in adult patients with advanced B-cell ALL
Patients with relapsed or refractory CD19-positive B-cell acute lymphoblastic leukemia (ALL) who were treated with the novel anti-CD19 chimeric...
MD Anderson launches Institute for Cell Therapy Discovery & Innovation to deliver transformational new therapies
The University of Texas MD Anderson Cancer Center today announced the launch of its Institute for Cell Therapy Discovery & Innovation,...
Novel triplet regimen yields promising response in advanced-phase chronic myeloid leukemia
According to researchers at The University of Texas MD Anderson Cancer Center, 80% of patients with previously untreated or relapsed/refractory...